Dislipidemia

Lipid Management Goals in Diabetes Diabetes is a CHD risk equivalent, as defined by the ATP III panel of the NCEP recommendations. Based on the evidence from the LDL-lowering clinical trials, most patients with diabetes should have an LDL goal  of <100 mg/dl. Following the more recent evidence from the newer statin trials, including the

The triglyceride-rich lipoproteins and low HDL-cholesterol are intimate components of the insulin resistancemediated pathophysiology. Unlike the evidence from a plethora of trials of CHD risk reduction with statins, the direct evidence from drugs to lower triglycerides or to raise HDL-cholesterol is relatively limited. A meta-analysis of 29 observational studies, encompassing more than 10,000 CHD cases

Given the heterogeneity of lipoproteins and the complexity of lipoprotein metabolism in patients with diabetes, the evidence-based approach to restore all of the pathophysiologic defects is still not well established. Since the mid 1990s a variety of randomized, controlled trials with HMG-CoA reductase inhibitors (statins) have established the efficacy of these LDL-lowering agents in reducing

Diabetes is the leading cause of cardiovascular morbidity and mortality around the world. On the basis of a number of epidemiologic studies and clinical trials, diabetes was designated a coronary heart disease (CHD)risk equivalent by the National Cholesterol Education Program’s Adult Treatment Panel III (ATPIII). The 10 yr risk of major CHD events in patients